Brexpiprazole in India and the United States: A Comparative Review of Regulatory Status, Clinical Evidence, Market Access, and Evidence Gaps

Natasha Gill, Supreet K Sohi, Neena Bhatti, Girish Joseph, Pallavi Abhilasha

Open source

DOI
10.7759/cureus.117032
Published
2026-09-27
Container
Cureus
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.7759/cureus.117032,
  title = {Brexpiprazole in India and the United States: A Comparative Review of Regulatory Status, Clinical Evidence, Market Access, and Evidence Gaps},
  author = {Natasha Gill and Supreet K Sohi and Neena Bhatti and Girish Joseph and Pallavi Abhilasha},
  year = {2026},
  journal = {Cureus},
  doi = {10.7759/cureus.117032},
  url = {https://doi.org/10.7759/cureus.117032}
}

RIS

TY  - JOUR
TI  - Brexpiprazole in India and the United States: A Comparative Review of Regulatory Status, Clinical Evidence, Market Access, and Evidence Gaps
AU  - Natasha Gill
AU  - Supreet K Sohi
AU  - Neena Bhatti
AU  - Girish Joseph
AU  - Pallavi Abhilasha
PY  - 2026
JO  - Cureus
DO  - 10.7759/cureus.117032
UR  - https://doi.org/10.7759/cureus.117032
ER  - 

APA

Gill, N., Sohi, S. K., Bhatti, N., Joseph, G., & Abhilasha, P. (2026). Brexpiprazole in India and the United States: A Comparative Review of Regulatory Status, Clinical Evidence, Market Access, and Evidence Gaps. Cureus. https://doi.org/10.7759/cureus.117032

Source records